XL-147

• CAT Number: I005548
• CAS Number: 934526-89-3
• Molecular Formula: C25H25ClN6O4S
• Molecular Weight: 541
• Purity: ≥95%
• Target: PI3K
• Solubility: DMSO: ≥ 43 mg/mL
• Storage: Store at -20°C
• IC50: 39 nM (PI3Kα); 383 nM (PI3Kβ); 36 nM (PI3Kδ); 23 nM(PI3Kγ)
• IUPAC Name: 2-amino-N-[3-[[3-(2-chloro-5-methoxyanilino)quinoxalin-2-yl]sulfamoyl]phenyl]-2-methylpropanamide
• InChI: InChI=1S/C25H25ClN6O4S/c1-25(2,27)24(33)28-15-7-6-8-17(13-15)37(34,35)32-23-22(29-19-9-4-5-10-20(19)30-23)31-21-14-16(36-3)11-12-18(21)26/h4-14H,27H2,1-3H3,(H,28,33)(H,29,31)(H,30,32)
• InChIKey: QINPEPAQOBZPOF-UHFFFAOYSA-N
• SMILES: COC1=CC(NC2=NC3=CC=CC=C3N=C2NS(C4=CC=CC(NC(C(C)(N)C)=O)=C4)(=O)=O)=C(Cl)C=C1

XL-147 (Cat.No:I005548) is a promising small molecule inhibitor with potential therapeutic applications. As a targeted therapy, it aims to inhibit specific enzymes involved in cellular processes, making it a candidate for cancer treatment and other diseases. Researchers are actively exploring XL-147’s mechanisms to unlock its full therapeutic potential.

Reference

[1]. Geoffrey I Shapiro, et al. Targeting Aberrant PI3K Pathway Signaling With XL147, a Potent, Selective, and Orally Bioavailable PI3K Inhibitor. 


[2]. Chakrabarty A, Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors. Cancer Res. 2013 Feb 1;73(3):1190-200. 


[3]. Reynolds CP, et al. Initial testing (stage 1) of the phosphatidylinositol 3/’ kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program. Pediatr Blood Cancer. 2013 May;60(5):791-8. 


[4]. Reynolds CP, et al. Initial testing (stage 1) of the phosphatidylinositol 3/’ kinase inhibitor, SAR245408 (XL147) by the pediatric preclinical testing program. Pediatr Blood Cancer. 2013 May;60(5):791-8.